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ORIGINAL ARTICLE
A consensus on the use of daylight photodynamic therapy in the UK
Sally Ibbotsona, Robin Stonesb, Jonathan Bowlingc,d, Sandra Campbelle, Stephen Kownackif,
Muthu Sivaramakrishnana, Ronan Valentineg and Colin A. Mortonh
aPhotobiology Unit, Department of Dermatology, Ninewells Hospital & Medical School, Dundee, UK; bDepartment of Dermatology, East Cheshire
NHS Trust, Macclesfield, UK; cPrivate Dermatology Practice, London, UK; dPrivate Dermatology Practise, Oxford, UK; eDermatology Department,
The Royal Cornwall Hospital, Truro, UK; fPrimary Care Dermatology Society, Hatfield, UK; gBeatson West of Scotland Cancer Centre, Glasgow,
UK; hDepartment of Dermatology, NHS Forth Valley, Stirling, UK
ABSTRACT
Background: Actinic keratoses (AKs) are a consequence of chronic exposure to ultraviolet radiation.
Treatment of chronically photo-damaged skin and AKs is driven by risk of progression to squamous cell
carcinoma, as well as for symptomatic relief. Conventional photodynamic therapy (c-PDT) is indicated
when AKs are multiple or confluent and if patients respond poorly or are unable to tolerate other thera-
pies. c-PDT is limited by the field size that can be treated in single sessions and can cause significant
discomfort.
Objective: Recent studies investigated daylight illumination to activate protoporphyrin IX and daylight-
PDT (d-PDT) is now licensed in the UK for face and scalp AKs. A group of experts met to discuss applica-
tion of d-PDT with methyl aminolevulinate (MAL) and develop a UK consensus statement, specific to UK
weather conditions.
Methods: The UK consensus recommendations were reached among eight experts, who reviewed recent
studies on d-PDT, assessed UK meteorological data and discussed personal experiences of d-PDT for AKs.
Results: Recommendations from these discussions provide guidance on d-PDT use, specifically regarding
patient selection, therapeutic indications, when to treat, skin preparation, MAL application and daylight
exposure for patients with AKs.
Conclusions: This UK expert consensus provides practical guidance for UK application of d-PDT.
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Introduction
Actinic keratoses (AKs) arising as a consequence of chronic expos-
ure to ultraviolet (UV) radiation appear most frequently on photo-
exposed sites of the head, neck, forearms and legs (1,2). Patients
may present for treatment because lesions are symptomatic or for
cosmetic reasons. However, the potential of AKs to progress to
invasive squamous cell carcinoma (SCC) is also usually a consider-
ation. Within areas of chronically photodamaged skin, there are
invariably visible AK lesions and subclinical areas of dysplasia,
which are not seen by the naked eye (field change cancerisation
[field AKs]). Management can therefore be divided into lesion-
directed or field-directed therapy. Treatment of field AKs is essen-
tial to treat subclinical disease but requires larger areas and
numbers of treatments (3). A field change approach offers treat-
ment of not only evident AKs but also subclinical disease (4,5).
The prevalence of AKs increases with age and cumulative sun-
light exposure and is also higher in fair-skinned individuals and
men (1,2,6). Field AKs are markedly increased in patients who are
immunosuppressed, with 40% of patients who have undergone
organ transplantation developing AKs within five years of the pro-
cedure (7) and a much greater risk (52- to 250-fold higher) of
lesions progressing to invasive SCC in the immunocompromised
population (5,8,9). AKs are a marker of significant UV exposure
and thus total skin examination is recommended and patients
should be educated regarding sun avoidance and protection.
A range of treatments are available for AKs. These include top-
ical field-directed treatments such as 5-fluorouracil, imiquimod,
ingenol mebutate and diclofenac in sodium hyaluronate; destruc-
tive therapies, including chemical peels, cryosurgery, dermabrasion
and laser; and photodynamic therapy (PDT) (4). Topical treatments
are widely used in primary care in the UK but have limitations,
particularly with the need for the patient to comply with their
treatment application. This can be of lengthy duration and cause
significant inflammatory adverse effects, which can also impact on
treatment compliance and completion (4). If patients are not able
to comply with topical therapies, or have failed other therapies,
then PDT is an appropriate field-directed treatment option.
Conventional PDT (c-PDT)
c-PDT involves the photoactivation of protoporphyrin IX (PpIX);
after pro-drug application and uptake, PpIX selectively accumu-
lates in the dysplastic or malignant cells, evident by visualisation
of the localised crimson red PpIX fluorescence. On illumination in
the presence of oxygen, photoactivation and photobleaching of
PpIX occurs, generating oxidative stress and reactive oxygen spe-
cies (ROS). This in turn initiates inflammation and cytotoxicity,
resulting in apoptosis and necrosis of abnormal cells (10). c-PDT
involves removal of any superficial crusting and scaling around
the AKs and then applying the photosensitiser pro-drug (such as
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methyl aminolevulinate [MAL]). This treatment is applied not only
to visible lesions but also to the surrounding field in order to
include subclinical lesions. Pro-drug absorption and conversion
into PpIX take place over a 3-h period with the cream under
occlusion. Photoactivation of PpIX is then undertaken with nar-
rowband red light (630 nm, light dose of 37.5 J/cm2), generally
using a light emitting diode (LED; e.g. Aktilite CL128) (11,12). The
only licensed pro-drugs in the UK for PDT for AK are MAL; Metvix
(Galderma, Watford, UK) and 5-aminolaevulinic acid in nanocolloid
emulsion ALA; Ameluz (Biofrontera, Leverkusen, Germany). PDT in
the UK employs red light irradiation, generally using LEDs, such as
Aktilite or RhodoLED, although many different types of red light
source could be used. In the US, ALA is licensed as Levulan
Kerastick for use with fluorescent blue light for PD for AK and
Metvixia is licensed for PDT for AK using a red light illumination
source.
PDT is a highly effective method of treating AKs, achieving up
to 90% clearance following one or two treatments, and is also an
important treatment option for superficial basal cell carcinoma
(BCC) and Bowen’s disease when surgical excision is considered
less appropriate (10,13). PDT is now included in several guidelines
for the treatment of AKs from the National Institute for Health
and Care Excellence (NICE), the Primary Care Dermatology Society
and the British Association of Dermatologists (4,14,15). High effi-
cacy, good cosmetic effects and the fact that PDT is generally well
tolerated result in high patient satisfaction for PDT (3).
There are two main aspects of the treatment that affect
patients’ amenability to the procedure: the duration of the treat-
ment and the degree of discomfort during illumination. With c-
PDT, pro-drug must be applied to the treatment area, occluded
and incubated prior to irradiation. The area that can be treated in
a single session is limited by the area of the static LED used and
is therefore limited to a 10 20 cm field. However, it is possible to
use multiple LEDs at the same time, although this is often not
practical as most centres do not have multiple sources and this
limits the number of patients that can be treated at any given
time. As most patients with field AKs have large areas of multiple
lesions, multiple visits to the hospital are required for c-PDT ses-
sions, resulting in inconvenience for patients and a significant
commitment for PDT clinics with regards to space and staff.
The discomfort of topical PDT has both neuropathic (16) and
inflammatory components and appears to be initiated during the
generation of ROS. The discomfort is usually described as a burn-
ing, prickling, neuropathic-like pain. Pain is most severe in patients
having large areas treated, during treatment of the face and scalp,
and treatment for AK lesions and methods to reduce pain are of
limited efficacy (17–19).
However, there is emerging evidence that low irradiance PDT
is associated with less discomfort and possibly increased efficiency
of PDT effects (20–22). One way to deliver very low irradiance PDT
is by the use of daylight to activate PpIX. It has been demon-
strated that for patients with AKs and in particular field AKs, PDT
using daylight can have a similar efficacy to c-PDT, is almost pain
free and produces excellent cosmetic results (22–30). However, it
is important to note that in these studies, the efficacy of d-PDT
was only followed up over 3–6 months, although with high
efficacy rates still apparent at six months (31,32) and this is also
typical of the follow-up interval used in most studies of most
treatments for AK.
Daylight PDT (d-PDT)
The wavelengths of light known to activate PpIX in the skin fall
within the visible spectrum of daylight (33). This use of an
abundant natural resource provides greater flexibility as well as
making it easier to treat larger areas of AKs, while being almost
pain free. However, the lower irradiance of daylight means that a
longer exposure time is required to achieve the same levels of
PpIX activation (33). Pre-illumination time, in contrast, is shorter
(<30min) because the absorption of pro-drug can continue dur-
ing daylight exposure and PpIX is continuously being produced
and activated. One explanation for the reduction in pain intensity
during d-PDT is that there is no significant PpIX accumulation
before illumination.
Thus, as can be seen from Figure 1 (34), there is maximal
absorption of PpIX in the blue light wavelengths of the solar spec-
trum and most of the effects of d-PDT are therefore attributed to
blue light PDT.
Clinical experience with d-PDT
Initial efficacy and safety studies of d-PDT with MAL were con-
ducted in Copenhagen (22–26). Subsequently, studies were con-
ducted in central and southern Europe, Brazil and Australia
(27,29–31). Patients in these studies mostly had mild-to-moderate
AKs on the face and scalp and duration of exposure varied
between studies (90–240min). This varies from the now licensed
exposure period of 2 h. Some patients remained in the hospital
grounds during the exposure period while others were allowed to
go home after pro-drug application. The two phase III studies per-
formed in Australia and Europe both used a continuous 2 h of
daylight exposure.
Despite the variation in exposure times, response rates have
been shown to be similar in various countries. In Europe, the
mean rate of clearance of AKs was 75–83% after one treatment
for patients with Grade I/II AKs (22–27,29). In Australia and Brazil,
the response was greater, at 89% and 88%, respectively, for
patients with mild AKs (30,31). Pain scores were generally low
with some studies demonstrating that d-PDT was almost pain free
(24,27). Individual patients who reported higher discomfort levels
had either increased the period between pro-drug application and
sunlight exposure or had covered breaks during the exposure
period, both of which result in increased time for intracellular con-
centrations of PpIX to increase (27,33).
A small study also compared the thickness of pro-drug applica-
tion and PpIX fluorescence to determine the optimal thickness for
d-PDT. No statistical difference was observed in PpIX fluorescence
with 0.1–1mm thickness of cream after 3 h incubation (35).
Studies by Wiegell and colleagues have concluded that
measurement of absolute light doses are not required in d-PDT
(33); however, the procedure does require daylight to reach a
critical threshold, above which efficacy appears to be independ-
ent of light irradiance. This threshold was estimated to be
8 J/cm2 and the conservative threshold for treatment has been
applied at 130 W/m2 (24). The temperature must also be warm
enough (judged as >10 C) for the patient to comfortably sit
outside for two hours. The requirement for the patient to be
outside also rules out treatment on rainy days unless suitable
indoor space is available with diffuse natural daylight (e.g. a
conservatory) and the day is not too overcast. Indirect sunlight
is sufficient for successful d-PDT, but if the skies are heavily
overcast, with no apparent daylight then we would not advise
d-PDT. In practice, it would only be these extreme conditions
that would be limiting and most of the time it is entirely feas-
ible to undertake effective d-PDT. For these reasons, while d-
PDT can be conducted year-round in southern Europe, in north-
ern Europe, it must be restricted to Spring, Summer and early
Autumn (36).
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The European consensus set out guidelines on the use of d-
PDT, providing a useful overview. However, in order that this
protocol is appropriate for use in the varying climatic conditions
throughout Europe, more specific guidelines are required. From a
UK perspective, seasonal variation in daylight hours and adverse
weather conditions may limit the usage of d-PDT seasonally and
at certain times of the day. The development of a UK-specific con-
sensus statement is therefore crucial in maximising the efficacy of
this treatment.
d-PDT in the UK
Recently, a group of experts met at the invitation of Galderma to
discuss the consensus protocol in the light of their own experi-
ence with d-PDT in the UK, and to make recommendations for UK
patients and healthcare professionals. The objectives of the meet-
ing were to investigate which types of patients may be most suit-
able for d-PDT, to establish clarity on the treatment protocol
during and after treatment, to consider the information that may
be required for patients and to investigate the extent to which
patients could potentially independently complete their treat-
ment/daylight exposure.
Daylight in the UK
Information on UK weather conditions (1986–2005) provided by
METEOTEST (Bern, Switzerland) using the meteonorm software
(www.meteonorm.com) was assessed by the group of experts to
determine when d-PDT can be undertaken (see Figure 2 and
Table 1; personal communication).
In the UK, patterns of daylight and rainfall mean that in areas
south of Nottingham, d-PDT is restricted to between March and
October, and in areas north of Nottingham it is restricted to
between March/April and September (when temperatures are
>10 C; personal communication). Overall it was agreed that if
d-PDT in the UK takes place within these seasonal boundaries it
can be assumed that there is sufficient light between 9:00 and
18:00, and there is no need to take light measurements. It has
recently been demonstrated that artificial light sources may also
be used, such as halogen and LED lamps in an indoor “daylight
room”. It was also shown that greenhouses are beneficial for
d-PDT in weather conditions which might be uncomfortable, such
as wind and rain (37).
Selection of patients for d-PDT
Accurate diagnosis of AK is a key factor when treating the condi-
tion. As set out in the European consensus statement, d-PDT is
most effective for Grades I and II AKs (36), the types of lesions
most commonly treated by the UK experts, in addition to areas of
field AKs or those with risk factors for developing SCC.
The location of the AKs will also impact the decision to use
d-PDT over c-PDT although in practice, d-PDT is likely to be
interspersed with c-PDT. d-PDT is particularly suited for treating
large field areas and areas that can be readily exposed to illu-
mination, such as the face and scalp. It is particularly suited to
patients with large areas of AKs due to the fact that it can be
Figure 1. Wavelength-dependent penetration of blue, green, yellow and red light in PDT. Arrows indicate the approximate 50% optical penetration depth in human
skin. Reproduced with permission (34).
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used to treat multiple lesions in a single treatment session.
Whilst d-PDT can be used at other sites, which can be
exposed to daylight, as the licensed regime is restricted to use
on face and scalp, we have limited our discussions to these
within license indications. It was recommended to continue
to use c-PDT for focussed hyperkeratotic lesions, BCCs,
areas affected by Bowen’s disease or sensitive areas (e.g.
around the eyes).
Patient preference will also be an important consideration in
the choice of therapy. Patients who have previously experienced
discomfort, side effects or treatment failure with c-PDT or other
topical treatment modalities, want a quicker one-off appointment
and those who are prepared to be outdoors for 2 h may prefer
d-PDT and be willing to comply with the protocol, even if incon-
venienced by rescheduling due to rain or the need for a second
treatment if there has been an incomplete response. If rain inter-
rupts the procedure within 30min, the MAL should be removed
and the procedure rescheduled (Table 2) however, if they have
received >30min exposure, an assessment can be made based on
the exposure time.
Within the public sector in the UK, the high number of
patients presenting with AKs who might benefit from treatment
results in consideration of all contributory costs by the National
Health Service (NHS). Under current NHS arrangements, GPs are
most likely to refer patients with large areas of sun-damaged
skin to a consultant for a definitive diagnosis and to formulate a
management plan. In the future, however, intermediate care
with a general practitioner with specialised interest (GPSI) in
dermatology could be a suitable setting for d-PDT, with
emphasis placed on establishing an accurate diagnosis in the
first instance.
d-PDT treatment protocol
Recently, Morton and colleagues published a European consensus
on the treatment of AKs, which details the d-PDT treatment proto-
col based on the results of recent clinical studies (36). Figure 3
summarises the protocol and how it varies from the protocol for
c-PDT.
Morton and colleagues not only considered the order and dur-
ation of the different steps in the procedure, but provided
detailed information on each step of the protocol (36). As with
the UK experts, they stress the simplicity and flexibility of d-PDT,
and it was agreed that it is likely to be robust enough to accom-
modate slight variations in the protocol (e.g. whether sunscreen is
applied before or after skin preparation). The UK licence recom-
mends the application of sunscreen beforehand.
In hospitals in the UK, lesion diagnosis is undertaken by the
doctor, but trained nurses or technicians will be primarily respon-
sible for the procedure and will probably prefer more specific
guidance on the items summarised in Table 2.
Patient considerations, information and understanding
It is essential that patients understand the reasons for their
treatment, how the treatment works and the procedure itself.
Figure 2. Meteorological data for the UK, showing the daily average light irradiances throughout the year between 09:00 and 18:00 (Panel a) and the days with
>1.0mm precipitation (Panel b; personal communication). The threshold above which efficacy appears to be independent of light irradiance (130 W/m2) (24) is indi-
cated by the dashed line.
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Information sheets should include pictorial diagrams of the
area(s) to be treated and the schedule and duration of each
step in the procedure. Table 3 summarises the key information
and protocol considerations that patients must understand prior
to treatment.
Reception staff at the hospital should also have this informa-
tion. As they will be involved in booking appointments, it is
important for them to understand the weather implications and
possible need to reschedule. This means that patients will need a
human interface for making appointments – secondary care book-
ing systems are not appropriate for this approach.
Setting for d-PDT
Secondary care
In the UK, the consensus group agreed that d-PDT will initially
predominantly take place in hospital clinics where c-PDT is cur-
rently performed, as initial accurate diagnosis is critical. The
patient could either remain at the hospital for the complete pro-
cedure, or undergo sunscreen application, lesion preparation and
pro-drug application at the hospital and then return home (or go
to an appropriate open space nearby) for daylight exposure and
treatment completion. Patients who do not remain at the hospital
should receive adequate information on the protocol before they
leave and also be given a contact number in case they have
questions.
If the patient is unable to return home or go to a suitable out-
door space nearby for daylight exposure within 30–45min of pro-
drug application, they will have to receive the full treatment at
the hospital. An appropriate risk-assessed designated space (either
outdoors or indoors) would be required and a certain level of
supervision would be required during treatment. This makes the
setting in clinics ideal, where several patients could be treated at
the same time to allow for group supervision.
Patients who live in rural settings and have to attend city
hospitals for treatment may not have the option to return home
to complete their treatment and may be unwilling to sit in a pub-
lic place for daylight exposure. Two potential scenarios can be
envisaged for these (and other) patients in the future: treatment
in primary/intermediate care or home-based care.
Primary/intermediate care
The faculty concluded that in the future, patients may have access
to a local GPSI in dermatology that could supervise treatment and
in some cases diagnose and initiate treatment. It was agreed that
it would initially be more likely that the consultant would refer
the patient to the GPSI for treatment following diagnosis. For this
to become a reality, it would be necessary to establish that there
was interest within primary/intermediate care, as currently it is not
seen as a key health issue in this setting. Other factors that would
need to be addressed are the need for appropriate training, the
cost of MAL compared with other potential treatment options,
and the need for endorsement from secondary care. One possible
solution could be for initial treatment to be administered in hos-
pital and any subsequent treatment to be given in intermediate
care, although a shared-care protocol would be required.
Summary and conclusions
Overall, it was agreed that d-PDT offers an effective therapeutic
option for suitable patients with field areas of AK on the face and
scalp compared with current therapies for AKs, particularly over
large areas. d-PDT offers a relatively straightforward, flexible and
almost pain free treatment option, which harnesses an abundant
Table 1. Information on average UK weather conditions 1986–2005 (personal
communication).
Average UK weather conditions for d-PDT
 Average temperatures were above 10 C from March to November in the
south (below 53L – south of Nottingham), and from April to October in
the north (above 53L).
 Average light irradiances were above 130 W/m2 (and hence were suffi-
cient for d-PDT) from March to September in the north and from March
to October in the south (Figure 2(a)).
 On average, 30–35% of days experience some rain between March and
October (Figure 2(b)). However, the time and duration of the rainfall were
not specified, i.e. it may have been brief or at night, bearing in mind that
d-PDT requires a two-hour rain-free exposure.
Table 2. d-PDT Protocol considerations.
Protocol consideration UK expert comment
Acceptable characteristics of
sunscreen
In order to block only UV (but allow visible
light to activate PpIX), a chemical sunscreen
without reflective filters must be used.
Skin preparation Using an emollient prior to treatment could be
sufficient instead of more formal preparation
as long as the lesions were thin. Otherwise,
standard preparation as for c-PDT (light cur-
ettage, using a disposable ring curette, with-
out local anaesthesia or any surface
bleeding, is standard practice prior to con-
ventional PDT, if there is surface crust or
hyperkeratosis).
Quantities of MAL to use For simplicity, one tube per area. Clinical stud-
ies have shown that dose (i.e. thickness of
layer) does not influence outcomes and less
is required compared with c-PDT (36). One
tube is sufficient to treat the face or scalp.
Time before exposure Exposure within 30min is ideal, longer time
before exposure can result in increased dis-
comfort due to PpIX accumulation.
Weather Treatment must be given in the recommended
months (Figure 2) but otherwise the weather
should not affect the decision to treat unless
it is too cold or wet for the patient to be
outside. If treatment is interrupted by rain
before the patient has received 30min
exposure, the MAL should be removed and
the patient's treatment should be resched-
uled for another day. If the patient has
received >30min exposure, response should
be assessed against the exposure time
achieved.
Impact of indoor breaks during
daylight exposure
Ideally, exposure should be continuous, and
indoor breaks should be kept to a minimum
to avoid further PpIX accumulation, which is
associated with an increased risk of
discomfort.
Removal of MAL It does not appear to matter how removal is
achieved but, for simplicity, the use of emol-
lient or water and drying with towels is
suggested.
Follow-up - Follow-up telephone call the next day to
establish that treatment was successfully
undertaken and to ask about adverse effects
may be advisable.
- Cover the treated area to avoid UV exposure
for 24 h.
- Immunocompetent patients – Next appoint-
ment usually six weeks to three months
depending on extent and severity of disease
treated.
- Immunocompromised patients – Usually 4–6
weeks.
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natural resource. Indeed, compared with the use of topical treat-
ments or c-PDT for field AKs, this technique could allow a much
larger area to be treated in a single session without significant
side effects.
The European consensus provided an important baseline from
which to develop guidelines for the use of d-PDT in the UK.
However, due to the reliance of the treatment on weather condi-
tions, localised guidelines are required in order that they are
Table 3. Patient understanding for treatment with d-PDT.
Key concepts patients should understand to undertake d-PDT:
- Why AKs are usually treated
- Other treatment options available for AKs
- How d-PDT works using visible light (not UV)
- How long it takes
- The risks and side effects of treatment and how to deal with them (e.g. information on cooling/flannels, moisturiser, no anti-inflammatories)
- How to choose the setting for their treatment (e.g. at home, hospital site, suitable off-site space) and the potential benefits of undertaking d-PDT such as
undertaking outdoor activities during the sun exposure phase
Patients should also understand the protocol, in particular:
- The necessity to protect normal skin with appropriate chemical sunscreen to limit UV exposure (as d-PDT only requires visible light) with a healthy message
regarding sun protection practices in general
- Include a clear message on suitable weather conditions and what to do regarding interruptions
- Dose/thickness of cream
- The necessity to limit the incubation time prior to daylight exposure to 30min maximum if possible to minimise discomfort during the illumination phase
- The need to avoid covered time/time indoors during the two hours of daylight exposure
- The need to avoid applying MAL to certain areas of the face (eyes/mouth etc.)
- The need to cover the area and avoid further exposure to natural daylight or intense internal lighting for 24 h after completing treatment
- The option to be available for a follow-up call the next day to record information on treatment and adverse effects should be considered
Figure 3. European consensus protocol for daylight photodynamic therapy (d-PDT) compared with protocol for conventional PDT (c-PDT). Adapted from (11,36).
Table 4. Summary of recommendations.
Summary of recommendations
1. Patients suitable for d-PDT may be those with:
- AKs Grades I and II on the face and scalp
- Multiple and widespread AKs (field areas)
- With good surface preparation using a disposable ring curette, it may be feasible to undertake successful PDT for Grade III AK, but this would be off licence
use and we would not recommend this as a treatment of choice
2. Patients who choose to remain at the hospital for the duration of the procedure should be provided with:
- An outdoor area, which has been risk assessed, and/or an appropriate indoor area for daylight exposure in case it rains
- Supervision during the exposure period; groups of patients could be treated at the same time to minimise pressure on staff
3. Patients who choose to leave the hospital following application of MAL should be provided with:
- Careful instructions about the importance of beginning daylight exposure within 30; the duration of the exposure period; what to do in the event of rain or
other interruption, and how to remove MAL at the end of the exposure period
4. Patient education and advice
- A simple video/animation explaining the treatment and protocol would be helpful for discussion with patients (and could ultimately be available online for
patients to refer to if they are completing care at home)
- General information on the treatment
- A free patient advice line to give patients access to advice (especially in the event that home treatment becomes possible) could also be helpful
- Future sun exposure and photoprotection advice for patients with AKs and with skin cancer
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relevant to the geographical location, taking into account seasonal
variation.
This PDT treatment approach also facilitates streamlining and
efficacy of PDT clinic services. The lack of specialist equipment
required, the option of doing other outdoor activities during illu-
mination and the potential for local or home-based treatment in
the future makes d-PDT an exciting new treatment option. The
recommendations made by the UK experts are summarised in
Table 4.
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